NKILT Therapeutics Inc.
NKILT Therapeutics is a biotech company focused on developing innovative cell therapies targeting cancer, starting with natural killer (NK) cells. They utilize proprietary Chimeric ILT-Receptor (CIR™) technology to create off-the-shelf, allogeneic NK cell therapies aimed at leukemias and solid tumors, with a focus on HLA-G expression in tumors. Their mission is to make next-generation cell therapy accessible and cost-effective for more cancer patients, leveraging novel technology and a dedicated team of experts in immunology, oncology, and cell therapy.
Industries
Nr. of Employees
small (1-50)
Products
Allogeneic gene‑modified NK cell therapy candidate targeting HLA-G
A preclinical allogeneic NK cell therapy program genetically modified to target HLA‑G, designed to directly kill tumor cells and modulate innate/adaptive immunity.
Immune cell engineering platform (IL T‑receptor based)
A platform for designing receptor-based targeting modules that can be applied to multiple immune cell types (NK, T, iNKT) to create fit‑for‑purpose therapies.
Allogeneic gene‑modified NK cell therapy candidate targeting HLA-G
A preclinical allogeneic NK cell therapy program genetically modified to target HLA‑G, designed to directly kill tumor cells and modulate innate/adaptive immunity.
Immune cell engineering platform (IL T‑receptor based)
A platform for designing receptor-based targeting modules that can be applied to multiple immune cell types (NK, T, iNKT) to create fit‑for‑purpose therapies.
Services
Collaborative preclinical and translational development
Partnerships for preclinical testing, construct development, and translational activities to support IND-enabling studies.
Scientific presentations and advisory participation
Presentation of platform and data at scientific conferences and participation in advisory roles to inform program strategy.
Investor relations and business development engagement
Provision of investor materials and contact channels for funding and partnership discussions.
Collaborative preclinical and translational development
Partnerships for preclinical testing, construct development, and translational activities to support IND-enabling studies.
Scientific presentations and advisory participation
Presentation of platform and data at scientific conferences and participation in advisory roles to inform program strategy.
Investor relations and business development engagement
Provision of investor materials and contact channels for funding and partnership discussions.
Expertise Areas
- Allogeneic cell therapy platform development
- Natural killer (NK) cell engineering
- Engineered T-cell therapies (CAR-T/CAR-NK)
- Preclinical and translational development
Key Technologies
- Chimeric ILT‑receptor engineering
- Allogeneic NK cell engineering
- CAR construct engineering (including dual‑control designs)
- Gene editing methods for immune cells